Information Provided By: 
Fly News Breaks for October 19, 2015
JAZZ
Oct 19, 2015 | 07:59 EDT
UBS said the recent selloff in Jazz Pharmaceuticals is a buying opportunity, as they believe management will make good decisions on licensing/business development and commercial execution. The firm, which also thinks concerns for the Xyrem franchise are overdone, reiterated its Buy rating and $210 price target on Jazz Pharmaceuticals shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
